{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T11:49:44Z","timestamp":1780141784014,"version":"3.54.0"},"reference-count":40,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This is an executive summary of the recent guidance produced by the Scottish Intercollegiate Guidelines Network (SIGN) dementia guideline group with regards to the investigation of suspected dementia. This is a sub-section of the broader SIGN 168 guideline released in November 2023. The guideline group included clinicians with expertise in Old Age Psychiatry, Neurology, Radiology, and Nuclear Medicine supported by colleagues from the SIGN and Healthcare Improvement Scotland teams. There was representation from carers and support organizations with experience of dementia, to ensure the recommendations were appropriate from the perspective of the people being assessed for possible dementia and their carers. As the 2018 National Institute for Health and Clinical Excellence (NICE) dementia review included a review of the evidenced investigation of dementia, the SIGN guideline development group decided to focus on a review on the up-to-date evidence regarding the role of imaging and fluid biomarkers in the diagnosis of dementia. To give context to the consideration of more advanced diagnostic biomarker investigations, the guideline and this summary include the NICE guidance on the use of standard investigations as well as more specialist investigations. The evidence review supports consideration of the use of structural imaging, nuclear medicine imaging, and established Alzheimer's cerebrospinal fluid biomarkers (amyloid and tau) in the diagnosis of dementia. Although routine use of amyloid positron emission tomography imaging was not recommended, its potential use, under specialist direction, in patients with atypical or young-onset presentations of suspected Alzheimer's dementia was included as a clinical good practice point.<\/jats:p>","DOI":"10.1055\/a-2332-6426","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T23:09:33Z","timestamp":1716592173000},"page":"012-020","source":"Crossref","is-referenced-by-count":5,"title":["Scottish Intercollegiate Guidelines Network Guidance on Dementia: The Investigation of Suspected Dementia (SIGN 168) with Focus on Biomarkers\u2014Executive Summary"],"prefix":"10.1055","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4316-2320","authenticated-orcid":false,"given":"Graham Andrew","family":"Mackay","sequence":"additional","affiliation":[{"name":"Department of Neurology, Aberdeen Royal Infirmary, Foresterhill, Aberdeen, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Gall","sequence":"additional","affiliation":[{"name":"Department of Neurology, Queen Elizabeth University Hospital, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Jampana","sequence":"additional","affiliation":[{"name":"Department of Neuroradiology, Queen Elizabeth University Hospital, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Sleith","sequence":"additional","affiliation":[{"name":"Healthcare Improvement Scotland, Edinburgh, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[{"name":"Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart and Chest Hospital, Liverpool, United Kingdom"},{"name":"Department of Clinical Medicine, Danish Center for Health Services Research, Aalborg University, Aalborg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the SIGN Dementia Guideline Development Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,6,11]]},"reference":[{"key":"ref4","first-page":"972685","article-title":"Diagnostic tests for Alzheimer's disease: rationale, methodology, and challenges","volume":"2010","author":"S E Mason","year":"2010","journal-title":"Int J Alzheimers Dis"},{"issue":"06","key":"ref5","first-page":"CD008782","article-title":"Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)","volume":"2014","author":"C Ritchie","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"ref6","volume-title":"The Neuropathologic Findings from a Group of 123 Patients Who Have Come to Autopsy from the Rochester Alzheimer Disease Project (RADP)","author":"A M Kazee","year":"1993"},{"issue":"01","key":"ref8","doi-asserted-by":"crossref","first-page":"e-1","DOI":"10.1016\/j.jalz.2013.01.002","article-title":"Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association","volume":"9","author":"K A Johnson","year":"2013","journal-title":"Alzheimers Dement"},{"issue":"06","key":"ref9","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1136\/practneurol-2019-002468","article-title":"Amyloid PET imaging in clinical practice","volume":"20","author":"M A Kolanko","year":"2020","journal-title":"Pract Neurol"},{"issue":"02","key":"ref10","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/ana.25968","article-title":"Diagnostic accuracy of amyloid versus 18F-fluorodeoxyglucose positron emission tomography in autopsy-confirmed dementia","volume":"89","author":"O H Lesman-Segev","year":"2021","journal-title":"Ann Neurol"},{"issue":"04","key":"ref11","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2967\/jnumed.119.230797","article-title":"Predictive value of 18F-florbetapir and 18F-FDG PET for conversion from mild cognitive impairment to alzheimer dementia","volume":"61","author":"G Blazhenets","year":"2020","journal-title":"J Nucl Med"},{"issue":"01","key":"ref12","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.dadm.2014.11.004","article-title":"A systematic review and meta-analysis of (18)F-labeled amyloid imaging in Alzheimer's disease","volume":"1","author":"J M Yeo","year":"2015","journal-title":"Alzheimers Dement (Amst)"},{"issue":"02","key":"ref13","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s00259-015-3228-x","article-title":"Diagnostic accuracy of (18)F amyloid PET tracers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis","volume":"43","author":"E Morris","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"07","key":"ref14","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1007\/s00259-020-05187-x","article-title":"Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives","volume":"48","author":"M Cotta Ramusino","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"02","key":"ref15","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3233\/JAD-171093","article-title":"A systematic review and aggregated analysis on the impact of amyloid PET brain imaging on the diagnosis, diagnostic confidence, and management of patients being evaluated for Alzheimer's disease","volume":"63","author":"E R Fantoni","year":"2018","journal-title":"J Alzheimers Dis"},{"issue":"09","key":"ref16","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1001\/jamaneurol.2018.1346","article-title":"Association of amyloid positron emission tomography with changes in diagnosis and patient treatment in an unselected memory clinic cohort: the ABIDE project","volume":"75","author":"A de Wilde","year":"2018","journal-title":"JAMA Neurol"},{"issue":"06","key":"ref17","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1007\/s00259-019-04297-5","article-title":"Clinical impact of [18F]flutemetamol PET among memory clinic patients with an unclear diagnosis","volume":"46","author":"A Leuzy","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"ref18","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s12149-022-01792-y","article-title":"Clinical impact of amyloid PET using 18F-florbetapir in patients with cognitive impairment and suspected Alzheimer's disease: a multicenter study","volume":"36","author":"H Matsuda","year":"2022","journal-title":"Ann Nucl Med"},{"issue":"13","key":"ref19","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/jama.2019.2000","article-title":"Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia","volume":"321","author":"G D Rabinovici","year":"2019","journal-title":"JAMA"},{"issue":"29","key":"ref20","doi-asserted-by":"crossref","first-page":"e16509","DOI":"10.1097\/MD.0000000000016509","article-title":"Impact of amyloid-PET in daily clinical management of patients with cognitive impairment fulfilling appropriate use criteria","volume":"98","author":"E M Trivi\u00f1o-Ib\u00e1\u00f1ez","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"03","key":"ref21","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1136\/jnnp-2017-316194","article-title":"Clinical utility of amyloid PET imaging with (18)F-florbetapir: a retrospective study of 100 patients","volume":"89","author":"C J Carswell","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"04","key":"ref24","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1080\/03007995.2016.1277197","article-title":"Clinical and cost implications of amyloid beta detection with amyloid beta positron emission tomography imaging in early Alzheimer's disease - the case of florbetapir","volume":"33","author":"J Hornberger","year":"2017","journal-title":"Curr Med Res Opin"},{"issue":"03","key":"ref25","first-page":"822","article-title":"Fluid biomarkers in dementia diagnosis","volume":"28","author":"S E Schindler","year":"2022","journal-title":"Continuum (Minneap Minn)"},{"issue":"08","key":"ref26","doi-asserted-by":"crossref","first-page":"e0221365","DOI":"10.1371\/journal.pone.0221365","article-title":"Amyloid-\u03b2 PET-correlation with cerebrospinal fluid biomarkers and prediction of Alzheimer's disease diagnosis in a memory clinic","volume":"14","author":"E G M\u00fcller","year":"2019","journal-title":"PLoS One"},{"issue":"02","key":"ref27","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3233\/JAD-141725","article-title":"Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort","volume":"44","author":"J L Seeburger","year":"2015","journal-title":"J Alzheimers Dis"},{"issue":"12","key":"ref28","doi-asserted-by":"crossref","first-page":"e11170","DOI":"10.15252\/emmm.201911170","article-title":"Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease","volume":"11","author":"S Palmqvist","year":"2019","journal-title":"EMBO Mol Med"},{"issue":"03","key":"ref29","first-page":"CD010803","article-title":"CSF tau and the CSF tau\/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)","volume":"3","author":"C Ritchie","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"03","key":"ref30","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3233\/JAD-132561","article-title":"Concordance between cerebrospinal fluid biomarkers and [11C]PIB PET in a memory clinic cohort","volume":"41","author":"M Zwan","year":"2014","journal-title":"J Alzheimers Dis"},{"issue":"02","key":"ref31","first-page":"CD010945","article-title":"Plasma and cerebrospinal fluid ABeta42 for the differential diagnosis of Alzheimer's disease dementia in participants diagnosed with any dementia subtype in a specialist care setting","volume":"2","author":"M Kokkinou","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"07","key":"ref32","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","article-title":"CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis","volume":"15","author":"B Olsson","year":"2016","journal-title":"Lancet Neurol"},{"issue":"03","key":"ref33","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1001\/archneur.56.3.303","article-title":"Mild cognitive impairment: clinical characterization and outcome","volume":"56","author":"R C Petersen","year":"1999","journal-title":"Arch Neurol"},{"issue":"03","key":"ref34","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2796.2004.01388.x","article-title":"Mild cognitive impairment as a diagnostic entity","volume":"256","author":"R C Petersen","year":"2004","journal-title":"J Intern Med"},{"issue":"08","key":"ref35","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1111\/j.1532-5415.2008.01820.x","article-title":"Two-year progression from mild cognitive impairment to dementia: to what extent do different definitions agree?","volume":"56","author":"F E Matthews","year":"2008","journal-title":"J Am Geriatr Soc"},{"issue":"11","key":"ref36","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.jalz.2018.07.220","article-title":"Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease","volume":"14","author":"L M Shaw","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"02","key":"ref37","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jalz.2015.08.003","article-title":"Performance and complications of lumbar puncture in memory clinics: results of the multicenter lumbar puncture feasibility study","volume":"12","author":"F H Duits","year":"2016","journal-title":"Alzheimers Dement"},{"issue":"04","key":"ref38","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/01.wad.0000194014.43575.fd","article-title":"Safety and acceptability of the research lumbar puncture","volume":"19","author":"E R Peskind","year":"2005","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"01","key":"ref39","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/alz.12372","article-title":"State-of-the-art of lumbar puncture and its place in the journey of patients with Alzheimer's disease","volume":"18","author":"H Hampel","year":"2022","journal-title":"Alzheimers Dement"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.dadm.2017.04.007","article-title":"Consensus guidelines for lumbar puncture in patients with neurological diseases","volume":"8","author":"S Engelborghs","year":"2017","journal-title":"Alzheimers Dement (Amst)"},{"issue":"01","key":"ref41","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13195-017-0243-0","article-title":"Cost-effectiveness of cerebrospinal biomarkers for the diagnosis of Alzheimer's disease","volume":"9","author":"S A Lee","year":"2017","journal-title":"Alzheimers Res Ther"},{"issue":"12","key":"ref44","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1136\/jnnp-2014-307662","article-title":"Biomarkers in dementia: clinical utility and new directions","volume":"85","author":"R M Ahmed","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"05","key":"ref45","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","article-title":"Blood biomarkers for Alzheimer's disease in clinical practice and trials","volume":"3","author":"O Hansson","year":"2023","journal-title":"Nat Aging"},{"issue":"11","key":"ref46","first-page":"CD012884","article-title":"18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)","volume":"11","author":"G Mart\u00ednez","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"ref47","first-page":"CD012883","article-title":"18F PET with florbetaben for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)","volume":"11","author":"G Mart\u00ednez","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"ref48","first-page":"CD012216","article-title":"18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)","volume":"11","author":"G Mart\u00ednez","year":"2017","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2332-6426.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T23:43:51Z","timestamp":1735947831000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2332-6426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,24]]},"references-count":40,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2025,1,3]]},"published-print":{"date-parts":[[2025,1]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2332-6426","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5,24]]},"published":{"date-parts":[[2024,5,24]]}}}